Q1 FY27 earnings call transcript filed; revenue up 16%, EBITDA down 7% YoY

Mgmt Guided Margin ImprovementMgmt Guided Margin PressureCfo Debt Reduction RoadmapOrder Pipeline DisclosedMgmt Evaded Key QuestionInvestor Communications View source PDF Explain this filing

GMMPFAUDLR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+4.0%1-day move

₹1015.00

prior close

₹1015.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.3+0.3-0.4-0.9+4.0+2.0+0.3+0.0+0.9—————

Up moveDown movePending

AI summary

GMM Pfaudler filed Q1 FY27 earnings call transcript. Revenue rose 16% YoY to INR 925 cr, EBITDA fell 7% YoY to INR 94 cr on pricing pressure, PAT more than doubled to INR 22 cr. Order intake INR 1,007 cr, backlog INR 2,289 cr (up 20% YoY). Management replaced regional setup with four global divisions (CRT, PPT, HET, PST). Aims for 15% EBITDA margin over time and plans to repay EUR 7 million debt by Q2 end. Pharma/glass-lined shows green shoots in India and US, peptides and CDMO driving order wins.

Likely market impact

Improved divisional disclosure and strong backlog are positives, but EBITDA decline and lack of a specific margin timeline may limit near-term re-rating.